Fabiana Moura Souza

Dr. Fabiana Moura Souza


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAna Raquel Batista de Carvalho
Ana Raquel Batista de Carvalho
GAGlória Stéphany Silva de Araújo
Glória Stéphany Silva de Araújo
FSFabiana Moura Souza
Fabiana Moura Souza
Telma Maria Evangelista de AraújoTelma Maria Evangelista de Araújo
Telma Maria Evangelista de Araújo
ARAna Raisla De Araujo Rodrigues
Ana Raisla De Araujo Rodrigues
MMMaria Eliete Batista Moura
Maria Eliete Batista Moura
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections and has long posed challenges to vaccine development because of historical safety concerns and the complexity of protective immunity. Recent advances in structural biology, maternal immunization, vaccines for older adults, and monoclonal antibodies have reshaped this field. This study aimed to analyze global research trends in RSV vaccine research using a bibliometric approach. Methods: A bibliometric study was conducted using records retrieved from the Web of Science Core Collection on April 1, 2026. Original articles and reviews published between 1968 and 2026 were selected through a title-based search strategy related to RSV and vaccination. Bibliometric indicators, citation patterns, collaboration networks, source distribution, and thematic structures were analyzed using Bibliometrix and Biblioshiny in R. Results: The final sample included 1,455 documents from 394 sources, with an annual growth rate of 8.7%. Scientific production increased markedly after 2010, with stronger acceleration after 2020. The United States led global output, followed by China, the United Kingdom, Canada, and the Netherlands. Vaccine was the most productive and locally influential source. Citation analysis identified the formalin-inactivated RSV vaccine studies from 1969 and the prefusion F protein study from 2013 as major intellectual milestones. Keyword analysis showed a shift from disease burden, epidemiology, and pathogenesis toward immunization, immunogenicity, maternal vaccination, older adults, and monoclonal antibodies. Conclusions: RSV vaccine research has evolved from a historically safety-constrained field to a mature translational area focused on prevention, implementation, real-world effectiveness, and equitable access.

30 September 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
ACAna Raquel Batista de Carvalho
Ana Raquel Batista de Carvalho
GAGlória Stéphany Silva de Araújo
Glória Stéphany Silva de Araújo
MCMaria Eduarda EDUARDA PEREIRA Pereira Correia
Maria Eduarda EDUARDA PEREIRA Pereira Correia
FSFabiana Moura Souza
Fabiana Moura Souza
Telma Maria Evangelista de AraújoTelma Maria Evangelista de Araújo
Telma Maria Evangelista de Araújo
MMMaria Eliete Batista Moura
Maria Eliete Batista Moura
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections and has long posed challenges to vaccine development due to historical safety concerns and the complexity of protective immunity. Recent advances in structural biology, maternal immunization, vaccines for older adults, and monoclonal antibodies have reshaped the field. This study aimed to analyze global research trends in RSV vaccine research using a bibliometric approach. Methods: A bibliometric study was conducted using records retrieved from the Web of Science Core Collection and Scopus on 1 September 2026. After database merging, deduplication, and data refinement, bibliometric indicators, citation patterns, collaboration networks, source distribution, and intellectual structure were analyzed using Bibliometrix and Biblioshiny in R. Results: The final corpus comprised 2516 documents published between 1968 and 2026 across 646 sources, with an annual growth rate of 10.7%. A total of 9298 authors were identified, with an average of 7.08 coauthors per document, and 24.56% of publications involved international collaboration. Scientific production increased markedly from the 2010s onward. The United States remained the leading contributor, while the most recent period showed broader participation from other countries. Vaccine was the most productive source. Citation analyses highlighted historical publications on the formalin-inactivated RSV vaccine and subsequent advances related to the prefusion F protein as important components of the field’s intellectual structure. Conclusions: RSV vaccine research has evolved from a historically safety-constrained field into a mature translational area focused on prevention, implementation, real-world effectiveness, and equitable access.